1
|
Shinde P, Howie HL, Stegmann TC, Hay AM, Waterman HR, Szittner Z, Bentlage AEH, Kapp L, Lissenberg-Thunnissen SN, Dekkers G, Schasfoort RBM, Ratcliffe SJ, Smolkin ME, Vidarsson G, van der Schoot CE, Hudson KE, Zimring JC. IgG Subclass Determines Suppression Versus Enhancement of Humoral Alloimmunity to Kell RBC Antigens in Mice. Front Immunol 2020; 11:1516. [PMID: 32765523 PMCID: PMC7378678 DOI: 10.3389/fimmu.2020.01516] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2020] [Accepted: 06/09/2020] [Indexed: 02/03/2023] Open
Abstract
It has long been appreciated that immunoglobulins are not just the effector endpoint of humoral immunity, but rather have a complex role in regulating antibody responses themselves. Donor derived anti-RhD IgG has been used for over 50 years as an immunoprophylactic to prevent maternal alloimmunization to RhD. Although anti-RhD has dramatically decreased rates of hemolytic disease of the fetus and newborn (for the RhD alloantigen), anti-RhD also fails in some cases, and can even paradoxically enhance immune responses in some circumstances. Attempts to generate a monoclonal anti-RhD have largely failed, with some monoclonals suppressing less than donor derived anti-RhD and others enhancing immunity. These difficulties likely result, in part, because the mechanism of anti-RhD remains unclear. However, substantial evidence exists to reject the common explanations of simple clearance of RhD + RBCs or masking of antigen. Donor derived anti-RhD is a mixture of 4 different IgG subtypes. To the best of our knowledge an analysis of the role different IgG subtypes play in immunoregulation has not been carried out; and, only IgG1 and IgG3 have been tested as monoclonals. Multiple attempts to elicit alloimmune responses to human RhD epitopes in mice have failed. To circumvent this limitation, we utilize a tractable animal model of RBC alloimmunization using the human Kell glycoprotein as an antigen to test the effect of IgG subtype on immunoregulation by antibodies to RBC alloantigens. We report that the ability of an anti-RBC IgG to enhance, suppress (at the level of IgM responses), or have no effect is a function of the IgG subclass in this model system.
Collapse
Affiliation(s)
- Paurvi Shinde
- Bloodworks Northwest Research Institute, Seattle, WA, United States
| | - Heather L Howie
- Department of Pathology, Carter Immunology Center, University of Virginia School of Medicine, Charlottesville, VA, United States
| | - Tamara C Stegmann
- Sanquin Research and Landsteiner Laboratory, Department of Experimental Immunohematology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands
| | - Ariel M Hay
- Department of Pathology, Carter Immunology Center, University of Virginia School of Medicine, Charlottesville, VA, United States
| | | | - Zoltan Szittner
- Sanquin Research and Landsteiner Laboratory, Department of Experimental Immunohematology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands
| | - Arthur E H Bentlage
- Sanquin Research and Landsteiner Laboratory, Department of Experimental Immunohematology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands
| | - Linda Kapp
- Bloodworks Northwest Research Institute, Seattle, WA, United States
| | - Suzanne N Lissenberg-Thunnissen
- Sanquin Research and Landsteiner Laboratory, Department of Experimental Immunohematology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands
| | - Gillian Dekkers
- Sanquin Research and Landsteiner Laboratory, Department of Experimental Immunohematology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands
| | - Richard B M Schasfoort
- Medical Cell Biophysics Group, MIRA Institute, University of Twente, Enschede, Netherlands
| | - Sarah J Ratcliffe
- Department of Pathology, Carter Immunology Center, University of Virginia School of Medicine, Charlottesville, VA, United States
| | - Mark E Smolkin
- Department of Pathology, Carter Immunology Center, University of Virginia School of Medicine, Charlottesville, VA, United States
| | - Gestur Vidarsson
- Sanquin Research and Landsteiner Laboratory, Department of Experimental Immunohematology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands
| | - C Ellen van der Schoot
- Sanquin Research and Landsteiner Laboratory, Department of Experimental Immunohematology, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands
| | - Krystalyn E Hudson
- Department of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, NY, United States
| | - James C Zimring
- Bloodworks Northwest Research Institute, Seattle, WA, United States.,Department of Pathology, Carter Immunology Center, University of Virginia School of Medicine, Charlottesville, VA, United States
| |
Collapse
|
2
|
Dekkers G, Bentlage AEH, Stegmann TC, Howie HL, Lissenberg-Thunnissen S, Zimring J, Rispens T, Vidarsson G. Affinity of human IgG subclasses to mouse Fc gamma receptors. MAbs 2017; 9:767-773. [PMID: 28463043 DOI: 10.1080/19420862.2017.1323159] [Citation(s) in RCA: 159] [Impact Index Per Article: 22.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022] Open
Abstract
Human IgG is the main antibody class used in antibody therapies because of its efficacy and longer half-life, which are completely or partly due to FcγR-mediated functions of the molecules. Preclinical testing in mouse models are frequently performed using human IgG, but no detailed information on binding of human IgG to mouse FcγRs is available. The orthologous mouse and human FcγRs share roughly 60-70% identity, suggesting some incompatibility. Here, we report binding affinities of all mouse and human IgG subclasses to mouse FcγR. Human IgGs bound to mouse FcγR with remarkably similar binding strengths as we know from binding to human ortholog receptors, with relative affinities IgG3>IgG1>IgG4>IgG2 and FcγRI>>FcγRIV>FcγRIII>FcγRIIb. This suggests human IgG subclasses to have similar relative FcγR-mediated biological activities in mice.
Collapse
Affiliation(s)
- Gillian Dekkers
- a Department of Experimental Immunohematology , Sanquin Research and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam , The Netherlands
| | - Arthur E H Bentlage
- a Department of Experimental Immunohematology , Sanquin Research and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam , The Netherlands
| | - Tamara C Stegmann
- a Department of Experimental Immunohematology , Sanquin Research and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam , The Netherlands
| | - Heather L Howie
- b Department of Transfusion Medicine , Bloodworks Northwest Research Institute , Seattle , Washington , USA
| | - Suzanne Lissenberg-Thunnissen
- a Department of Experimental Immunohematology , Sanquin Research and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam , The Netherlands
| | - James Zimring
- b Department of Transfusion Medicine , Bloodworks Northwest Research Institute , Seattle , Washington , USA
| | - Theo Rispens
- c Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Academic Medical Center , University of Amsterdam , The Netherlands
| | - Gestur Vidarsson
- a Department of Experimental Immunohematology , Sanquin Research and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam , The Netherlands
| |
Collapse
|
3
|
Howie HL, Delaney M, Wang X, Er LS, Vidarsson G, Stegmann TC, Kapp L, Lebedev JN, Wu Y, AuBuchon JP, Zimring JC. Serological blind spots for variants of human IgG3 and IgG4 by a commonly used anti-immunoglobulin reagent. Transfusion 2016; 56:2953-2962. [PMID: 27632931 DOI: 10.1111/trf.13812] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/01/2015] [Revised: 08/02/2016] [Accepted: 08/07/2016] [Indexed: 11/30/2022]
Abstract
BACKGROUND Human immunoglobulin G (IgG) includes four different subtypes (IgG1, IgG2, IgG3, and IgG4), and it is also now appreciated that there are genetic variations within IgG subtypes (called isoallotypes). Twenty-nine different isoallotypes have been described, with 7, 4, 15, and 3 isoallotypes described for IgG1, IgG2, IgG3, and IgG4, respectively. The reactivity of anti-IgG with different isoallotypes has not been characterized. STUDY DESIGN AND METHODS A novel monoclonal anti-K antibody (PugetSound Monoclonal Antibody 1 [PUMA1]) was isolated and sequenced, and a panel of PUMA1 variants was expressed, consisting of the 29 known IgG isoallotypes. The resulting panel of antibodies was preincubated with K-positive red blood cells (RBCs) and then subjected to testing with currently approved anti-IgG by flow cytometry, solid phase systems, gel cards, and tube testing. RESULTS A US Food and Drug Administration (FDA)-approved monoclonal anti-IgG (gamma-clone) failed to recognize 2 of 15 IgG3 isoallotypes (IgG3-03 and IgG3-13) and 3 of 3 IgG4 isoallotypes (IgG4-01, IgG4-02, and IgG4-03). In contrast, an FDA-approved rabbit polyclonal anti-IgG recognized each of the known human IgG isoallotypes. CONCLUSION These findings demonstrate "blind spots" in isoalloantibody detection by a monoclonal anti-IgG. If a patient has anti-RBC antibodies predominantly of an IgG3 subtype (the IgG3-03 and/or IgG3-13 variety), then it is possible that a clinically significant alloantibody would be missed. IgG-03 and IgG-13 have an estimated frequency of 1% to 3% in Caucasian populations and 20% to 30% in certain African populations. Nonreactivity with IgG4 is a known characteristic of this monoclonal anti-IgG, but IgG4 isoallotypes have not been previously reported.
Collapse
Affiliation(s)
| | - Meghan Delaney
- BloodworksNW Research Institute.,Departments of Laboratory Medicine and Internal Medicine, Division of Hematology, University of Washington, Seattle, Washington
| | | | | | - Gestur Vidarsson
- Department of Experimental Immunohematology, Sanquin Research and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
| | - Tamara C Stegmann
- Department of Experimental Immunohematology, Sanquin Research and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
| | | | | | | | - James P AuBuchon
- BloodworksNW Research Institute.,Departments of Laboratory Medicine and Internal Medicine, Division of Hematology, University of Washington, Seattle, Washington
| | - James C Zimring
- BloodworksNW Research Institute.,Departments of Laboratory Medicine and Internal Medicine, Division of Hematology, University of Washington, Seattle, Washington
| |
Collapse
|
4
|
Stegmann TC, Ji Y, Bijman R, Wang Z, Wen J, Wei L, Veldhuisen B, Haer‐Wigman L, Lighthart P, Lodén‐van Straaten M, Luo G, van der Schoot CE. Identification of a novel frequentRHCE*ce308Tvariant allele in Chinese D– individuals, resulting in a C+c– phenotype. Transfusion 2016; 56:2314-21. [DOI: 10.1111/trf.13709] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2016] [Revised: 04/28/2016] [Accepted: 05/05/2016] [Indexed: 11/26/2022]
Affiliation(s)
- Tamara C. Stegmann
- Sanquin Research and Landsteiner LaboratoryAcademic Medical Centre, University of AmsterdamAmsterdam The Netherlands
| | - Yanli Ji
- Institute of Clinical Blood Transfusion, Guangzhou Blood CenterGuangzhou China; and
| | - Renate Bijman
- Sanquin Research and Landsteiner LaboratoryAcademic Medical Centre, University of AmsterdamAmsterdam The Netherlands
| | - Zhen Wang
- Institute of Clinical Blood Transfusion, Guangzhou Blood CenterGuangzhou China; and
| | - Jizhi Wen
- Institute of Clinical Blood Transfusion, Guangzhou Blood CenterGuangzhou China; and
| | - Ling Wei
- Institute of Clinical Blood Transfusion, Guangzhou Blood CenterGuangzhou China; and
| | - Barbera Veldhuisen
- Sanquin Research and Landsteiner LaboratoryAcademic Medical Centre, University of AmsterdamAmsterdam The Netherlands
| | - Lonneke Haer‐Wigman
- Sanquin Research and Landsteiner LaboratoryAcademic Medical Centre, University of AmsterdamAmsterdam The Netherlands
| | | | | | - Guangping Luo
- Institute of Clinical Blood Transfusion, Guangzhou Blood CenterGuangzhou China; and
| | - C. Ellen van der Schoot
- Sanquin Research and Landsteiner LaboratoryAcademic Medical Centre, University of AmsterdamAmsterdam The Netherlands
| |
Collapse
|
5
|
Stegmann TC, Veldhuisen B, Bijman R, Thurik FF, Bossers B, Cheroutre G, Jonkers R, Ligthart P, de Haas M, Haer-Wigman L, van der Schoot CE. Frequency and characterization of known and novel RHD variant alleles in 37 782 Dutch D-negative pregnant women. Br J Haematol 2016; 173:469-79. [PMID: 27018217 DOI: 10.1111/bjh.13960] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2015] [Accepted: 12/14/2015] [Indexed: 11/30/2022]
Abstract
To guide anti-D prophylaxis, Dutch D- pregnant women are offered a quantitative fetal-RHD-genotyping assay to determine the RHD status of their fetus. This allowed us to determine the frequency of different maternal RHD variants in 37 782 serologically D- pregnant women. A variant allele is present in at least 0·96% of Dutch D- pregnant women The D- serology could be confirmed after further serological testing in only 54% of these women, which emphasizes the potential relevance of genotyping of blood donors. 43 different RHD variant alleles were detected, including 15 novel alleles (11 null-, 2 partial D- and 2 DEL-alleles). Of those novel null alleles, one allele contained a single missense mutation (RHD*443C>G) and one allele had a single amino acid deletion (RHD*424_426del). The D- phenotype was confirmed by transduction of human D- erythroblasts, consolidating that, for the first time, a single amino acid change or deletion causes the D- phenotype. Transduction also confirmed the phenotypes for the two new variant DEL-alleles (RHD*721A>C and RHD*884T>C) and the novel partial RHD*492C>A allele. Notably, in three additional cases the DEL phenotype was observed but sequencing of the coding sequence, flanking introns and promoter region revealed an apparently wild-type RHD allele without mutations.
Collapse
Affiliation(s)
- Tamara C Stegmann
- Sanquin Research and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands
| | - Barbera Veldhuisen
- Sanquin Research and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands.,Sanquin Diagnostic Services, Amsterdam, The Netherlands
| | - Renate Bijman
- Sanquin Research and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands
| | - Florentine F Thurik
- Sanquin Research and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands
| | | | | | - Remco Jonkers
- Sanquin Diagnostic Services, Amsterdam, The Netherlands
| | | | - Masja de Haas
- Sanquin Research and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands.,Sanquin Diagnostic Services, Amsterdam, The Netherlands
| | - Lonneke Haer-Wigman
- Sanquin Research and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands
| | - C Ellen van der Schoot
- Sanquin Research and Landsteiner Laboratory, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands
| |
Collapse
|
6
|
Haer-Wigman L, Stegmann TC, Solati S, Ait Soussan A, Beckers E, van der Harst P, van Hulst-Sundermeijer M, Ligthart P, van Rhenen D, Schepers H, de Haas M, van der Schoot CE. Impact of genetic variation in the SMIM1 gene on Vel expression levels. Transfusion 2015; 55:1457-66. [PMID: 25647324 DOI: 10.1111/trf.13014] [Citation(s) in RCA: 20] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/31/2014] [Revised: 10/07/2014] [Accepted: 10/21/2014] [Indexed: 01/12/2023]
Abstract
BACKGROUND Serologic determination of the Vel- phenotype is challenging due to variable Vel expression levels. In this study we investigated the genetic basis for weak Vel expression levels and developed a high-throughput genotyping assay to detect Vel- donors. STUDY DESIGN AND METHODS In 548 random Caucasian and 107 Vel+(w) donors genetic variation in the SMIM1 gene was studied and correlated to Vel expression levels. A total of 3366 Caucasian, 621 black, and 333 Chinese donors were screened with a high-throughput genotyping assay targeting the SMIM1*64_80del allele. RESULTS The Vel+(w) phenotype is in most cases caused by the presence of one SMIM1 allele carrying the major allele of the rs1175550 SNP in combination with a SMIM1*64_80del allele or in few cases caused by the presence of the SMIM1*152T>A or SMIM1*152T>G allele. In approximately 6% of Vel+(w) donors genetic factors in SMIM1 could not explain the weak expression. We excluded the possibility that lack of expression of another blood group system was correlated with weak Vel expression levels. Furthermore, using a high-throughput Vel genotyping assay we detected two Caucasian Vel- donors. CONCLUSION Weak Vel expression levels are caused by multiple genetic factors in SMIM1 and probably also by other genetic or environmental factors. Due to the variation in Vel expression levels, serologic determination of the Vel- phenotype is difficult and a genotyping assay targeting the c.64_80del deletion in SMIM1 should be used to screen donors for the Vel- phenotype.
Collapse
Affiliation(s)
- Lonneke Haer-Wigman
- Sanquin Research, Amsterdam and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands
| | - Tamara C Stegmann
- Sanquin Research, Amsterdam and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands
| | - Shabnam Solati
- Sanquin Research, Amsterdam and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands
| | - Aïcha Ait Soussan
- Sanquin Research, Amsterdam and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands
| | - Erik Beckers
- Maastricht University Medical Center, Maastricht, the Netherlands
| | | | - Marga van Hulst-Sundermeijer
- Department of Stem Cell Biology & Department of Experimental Hematology, Sanquin Diagnostic Services, Amsterdam, the Netherlands
| | - Peter Ligthart
- Sanquin Research, Amsterdam and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands
| | | | - Hein Schepers
- University Medical Center Groningen, University of Groningen, Groningen, the Netherlands
| | - Masja de Haas
- Sanquin Research, Amsterdam and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands
| | - C Ellen van der Schoot
- Sanquin Research, Amsterdam and Landsteiner Laboratory, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands
| |
Collapse
|